ST. HELIER, Jersey--(BUSINESS WIRE)--
Novocure (NASDAQ: NVCR) announced today that it will host an investor
event with Zai Lab on Nov. 14, 2018, in Shanghai, China. William Doyle,
Novocure’s Executive Chairman, Dr. Samantha Du, Zai Lab’s CEO, and Tao
Fu, Zai Lab’s President and Chief Operating Officer, will review the
strategic collaboration for Tumor Treating Fields in Greater China and
address questions from the audience.
The investor event will be held in conjunction with the
BioCentury-BayHelix China Healthcare Summit 2018 and will begin at 2:30
p.m. China Time. A webcast of the presentation will be accessible from
the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations,
for at least 14 days following the event.
About Novocure
Novocure is an oncology company developing a profoundly different cancer
treatment utilizing a proprietary therapy called Tumor Treating Fields,
the use of electric fields tuned to specific frequencies to disrupt
solid tumor cancer cell division. Novocure’s commercialized product is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating Tumor Treating
Fields in brain metastases, non-small cell lung cancer, pancreatic
cancer, ovarian cancer, liver cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.
About Zai Lab
Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical
company focused on bringing transformative medicines for cancer,
autoimmune and infectious diseases to patients in China and around the
world. The Company’s experienced team has secured partnerships with
leading global biopharma companies, generating a broad pipeline of
innovative drug candidates targeting the fast-growing segments of
China’s pharmaceutical market and global unmet medical needs. Zai Lab’s
vision is to become a fully integrated biopharmaceutical company,
discovering, developing, manufacturing and commercializing its partners’
and its own products in order to impact human health worldwide.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
development of potential products, interpretation of clinical results,
prospects for regulatory submission and approval, manufacturing
development and capabilities, market prospects for its products,
coverage, collections from third-party payers and other statements
regarding matters that are not historical facts. You may identify some
of these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ materially
from those reflected in these forward-looking statements due to general
financial, economic, regulatory and political conditions as well as more
specific risks and uncertainties facing Novocure such as those set forth
in its Annual Report on Form 10-K filed on February 22, 2018, with the
U.S. Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may prove
to be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend to
update publicly any forward-looking statement, except as required by
law. Any forward-looking statements herein speak only as of the date
hereof. The Private Securities Litigation Reform Act of 1995 permits
this discussion.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181107005769/en/
Novocure
Media and Investor Contact:
Ashley Cordova,
212-767-7558
acordova@novocure.com
Source: Novocure